We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Novel hormone is safe and effective in men receiving radiotherapy for prostate cancer.
- Authors
Nierengarten, Mary Beth
- Abstract
A post hoc analysis of two randomized clinical trials published in JAMA Oncology has found that relugolix, a novel hormone, is safe and effective in men undergoing radiotherapy for localized or advanced prostate cancer. The analysis included 260 patients, with significant castration rates observed in those who received relugolix. The study also found that relugolix demonstrated a faster return to baseline testosterone levels compared to traditional therapies, which could reduce adverse impacts associated with long-term testosterone suppression. However, some experts question the clinical significance of the more rapid recovery of testosterone levels with relugolix and note that the study is not large enough to determine differences in cancer-specific outcomes.
- Subjects
RADIOTHERAPY; PROSTATE cancer; CANCER radiotherapy; LUTEINIZING hormone releasing hormone receptors; ANDROGEN deprivation therapy; PROSTATE cancer patients
- Publication
Cancer (0008543X), 2024, Vol 130, Issue 14, p2408
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.35422